| Literature DB >> 35953796 |
Pasquale Scognamiglio1, Matthias Reeh2, Nathaniel Melling2, Marcus Kantowski3, Ann-Kathrin Eichelmann4, Seung-Hun Chon5, Nader El-Sourani6, Gerhard Schön7, Alexandra Höller7, Jakob R Izbicki2, Michael Tachezy2.
Abstract
Despite a significant decrease of surgery-related mortality and morbidity, anastomotic leakage still occurs in a significant number of patients after esophagectomy. The two main endoscopic treatments in case of anastomotic leakage are self-expanding metal stents (SEMS) and the endoscopic vacuum therapy (EVT). It is still under debate, if one method is superior to the other. Therefore, we performed a systematic review and meta-analysis of the existing literature to compare the effectiveness and the related morbidity of SEMS and EVT in the treatment of esophageal leakage. We systematically searched for studies comparing SEMS and EVT to treat anastomotic leak after esophageal surgery. Predefined endpoints including outcome, treatment success, endoscopy, treatment duration, re-operation rate, intensive care and hospitalization time, stricture rate, morbidity and mortality were assessed and included in the meta-analysis. Seven retrospective studies including 338 patients matched the inclusion criteria. Compared to stenting, EVT was significantly associated with higher healing (OR 2.47, 95% CI [1.30 to 4.73]), higher number of endoscopic changes (pooled median difference of 3.57 (95% CI [2.24 to 4.90]), shorter duration of treatment (pooled median difference - 11.57 days; 95% CI [- 17.45 to - 5.69]), and stricture rate (OR 0.22, 95% CI [0.08 to 0.62]). Hospitalization and intensive care unit duration, in-hospital mortality rate, rate of major and treatment related complications, of surgical revisions and of esophago-tracheal fistula failed to show significant differences between the two groups. Our analysis indicates a high potential for EVT, but because of the retrospective design of the included studies with potential biases, these results must be interpreted with caution. More robust prospective randomized trials should further investigate the potential of the two procedures.Entities:
Keywords: Anastomotic leakage; Endoscopic stenting; Esophagectomy; Vacuum therapy
Mesh:
Year: 2022 PMID: 35953796 PMCID: PMC9367146 DOI: 10.1186/s12893-022-01764-z
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1PRISMA flow diagram of study selection
Patient characteristics
| Publication year | Author | Initial treatment method | Country | Patients (n) | Female (n) | (%) | Age (Median (Range)) | Oncologic resection (%) | Neoadjuvant therapy (%) | Etiology: surgical anastomic leak (%) | Subtotal esophagectomy (%) | Reconstruction type esophagogastrostomy (%) | Cervical leak | % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | Brangewitz | EVT | Germany | 32 | 4 | 13 | 63 (45–84) | 88 | 56 | 94 | 44 | – | – | |
| SEMS | 39 | 9 | 23 | 62 (32–78) | 74 | 15 | 79 | 69 | – | – | ||||
| 2013 | Schniewind | EVT | Germany | 17 | – | – | – | – | – | 100 | 100 | – | 3 | 18 |
| SEMS | 12 | – | – | – | – | – | 100 | 100 | – | 1 | 8 | |||
| 2015 | Mennigen | EVT | Germany | 15 | 1 | 7 | 56 (42–76) | 100 | 73 | 100 | 100 | 100 | 0 | 0 |
| SEMS | 30 | 9 | 30 | 66 (40–92) | 96 | 43 | 100 | 100 | 100 | 0 | 0 | |||
| 2016 | Hwang | EVT | South Korea | 7 | 2 | 29 | 71 (63–78) | 100 | – | 100 | 71 | – | 0 | 0 |
| SEMS | 11 | 2 | 18 | 67 (55–81) | 100 | – | 100 | 36 | – | 1 | 9 | |||
| 2018 | Berlth | EVT | Germany | 35 | 5 | 14 | 65 (43–84) | 100 | 53 | 100 | 74 | 74 | 1 | 3 |
| SEMS | 76 | 14 | 18 | 64 (43–88) | 100 | 65 | 100 | 88 | 88 | 0 | 0 | |||
| 2021 | Eichelmann | EVT | Germany | 30 | 3 | 12 | 60 (42–78) | 100 | 80 | 100 | 100 | 100 | 0 | 0 |
| SEMS | 14 | 3 | 23 | 65 (37–88) | 100 | 62 | 100 | 100 | 100 | 0 | 0 | |||
| 2021 | El-Sourani | EVT | Germany | 13 | 1 | 8 | 60(49–75) | 100 | 10 | 100 | 100 | 100 | 0 | 0 |
| SEMS | 7 | 2 | 28 | 56 (49–69) | 100 | 3 | 100 | 100 | 100 | 0 | 0 |
ROBINS-I Scoring of the selected studies
| Study | Study type | Pre-intervention | At intervention | Post-intervention | Overall | ||||
|---|---|---|---|---|---|---|---|---|---|
| Confounding | Selection | Classification of intervention | Deviation from intervention | Missing data | Measurement of outcomes | Selection of reported results | |||
| Brangewitz et al. | Retrospective | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 2 |
| Schniewind et al. | Retrospective | 3 | 2 | 1 | 1 | 3 | 3 | 2 | 3 |
| Mennigen et al. | Retrospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hwang et al. | Retrospective | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 |
| Berlth et al. | Retrospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Eichelmann et al. | Retrospective | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 |
| El Sourani et al. | Retrospective | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Patient outcome
| Year | Author | Initial treatment method | Patients (n) | Median Number of stents/ sponges (range) | Median days treatment duration (range) | Successful closure rate (n) | Treatment related complications (n) | Majpr complications (n) | Esophago- tracheal fistula (n) | Surgical revision (n) | Stricture (n) | Time on ICU days | Median hospitalization in days (range) | In hospital mortality (n) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | Brangewitz | EVT | 32 | 7 (5–28) | 23 (9–86) | 27 | 8 | 3 | 1 | 1 | 3 | - | 48.5 (21–122) (mean und range) | 5 |
| SEMS | 39 | 3 (2–6) | 33 (9–132) | 21 | 8 | 6 | 0 | 3 | 11 | - | 41 (2–93) (mean und range) | 11 | ||
| 2013 | Schniewind | EVT | 17 | – | – | – | – | – | – | 0 | – | 26 ± 19 (mean + SD) | 57 ± 30 (mean und SD) | 2 |
| SEMS | 12 | – | – | – | – | – | – | 2 | – | 38 ± 32 (mean + SD) | 62 ± 39 (mean + SD) | 5 | ||
| 2015 | Mennigen | EVT | 15 | 6.5 (1–18) | 26,5 (3–75) | 14 | 0 | 0 | 0 | 0 | – | – | 58 (23–106) | 1 |
| SEMS | 30 | 1 (1–6) | 36 (1–156) | 19 | 1 | 3 | 1 | 4 | – | – | 53 (13–195) | 8 | ||
| 2016 | Hwang | EVT | 7 | 4.3 (2–10) | 27 (2–84) | 7 | 0 | 0 | – | 0 | – | – | 37.1 (13–128) | – |
| SEMS | 11 | 1.6 (1–4) | 19.5 (5–21) | 7 | 6 | 5 | – | 3 | – | – | 87.3 (17–366) | – | ||
| 2018 | Berlth | EVT | 34 | 3 (1–9) | 12 (3–58) | 24 | 4 | – | 0 | 0 | 1 | Median 6 (0–60) | 37 (19–118) | 3 |
| SEMS | 77 | 1 (1–3) | 27 (1–152) | 49 | 18 | – | 4 | 0 | 5 | Median 9 (0–295) | 38 (13–296) | 11 | ||
| 2021 | Eichelmann | EVT | 30 | 6 (1–25) | 23 (3–101) | 28 | – | – | – | – | 1 | Median 18 (4–107) | 47 (14–119) | 5 |
| SEMS | 14 | 1 (1–3) | 44 (11–68) | 13 | – | – | – | – | 5 | Median 18 (8–38) | 34 (17–56) | 1 | ||
| 2021 | El Sourani | EVT | 13 | 5 (4–18) | 24.5 (8–80 | 12 | 0 | 4 | – | 5 | – | Median 38 (9–193) | 74 (9–193) | 5 |
| SEMS | 7 | 1 (1–2) | 22 (3–31) | 6 | 2 | 2 | – | 1 | – | Median 20 (16–57) | 41 (22–123) | 1 |
Fig. 2Closure rate
Fig. 3A Number of endoscopic stent/sponge changes, B endoscopic treatment duration, C duration of hospitalization, D duration of intensive care unit stay
Fig. 4A Treatment related complications, B major complications, C esophago-tracheal fistula, D esophageal stenosis/stricture
Fig. 5A Re-operation, B in-hospital mortality